Telithromycin

Drug Profile

Telithromycin

Alternative Names: HMR-3647; Ketek; RU-647; RU-66647

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator sanofi-aventis
  • Developer Sanofi; sanofi-aventis
  • Class Antibacterials; Ketolides
  • Mechanism of Action Protein 50S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Marketed Acute exacerbations of chronic bronchitis; Acute sinusitis; Community-acquired pneumonia; Gram-positive infections; Pharyngitis; Respiratory tract infections; Tonsillitis
  • Discontinued Obstetric and gynaecological infections; Pelvic inflammatory disorders; Skin and soft tissue infections; Toxoplasmosis

Most Recent Events

  • 30 Mar 2007 The EMEA has recommended restricted use of telithromycin in the treatment of bronchitis, sinusitis and tonsilitis/pharyngitis
  • 13 Feb 2007 Withdrawn for Acute exacerbations of chronic bronchitis in USA (PO)
  • 13 Feb 2007 Withdrawn for Acute sinusitis in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top